Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Common Equity: 2021-2025

Historic Common Equity for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to $161.8 million.

  • Prime Medicine's Common Equity fell 14.61% to $161.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.8 million, marking a year-over-year decrease of 14.61%. This contributed to the annual value of $153.1 million for FY2024, which is 15.09% up from last year.
  • Prime Medicine's Common Equity amounted to $161.8 million in Q3 2025, which was up 165.89% from $60.9 million recorded in Q2 2025.
  • Prime Medicine's 5-year Common Equity high stood at $316.3 million for Q4 2022, and its period low was -$223.1 million during Q3 2022.
  • Its 3-year average for Common Equity is $178.0 million, with a median of $189.5 million in 2024.
  • Examining YoY changes over the last 5 years, Prime Medicine's Common Equity showed a top increase of 302.43% in 2022 and a maximum decrease of 136.29% in 2022.
  • Prime Medicine's Common Equity (Quarterly) stood at -$156.2 million in 2021, then soared by 302.43% to $316.3 million in 2022, then tumbled by 57.92% to $133.1 million in 2023, then grew by 15.09% to $153.1 million in 2024, then declined by 14.61% to $161.8 million in 2025.
  • Its last three reported values are $161.8 million in Q3 2025, $60.9 million for Q2 2025, and $106.9 million during Q1 2025.